Conference call for investors, analysts and the media
The report for 2016 will be presented by Alligator’s CEO Per Norlén and members of the management team of the company.
Time: Friday, February 17, 2017, at 10:00 (CET).
Telephone number of participants:
Europe: +44 (0) 2030089803
Sweden: +46 856642696
US +1 8558315946
The conference call will be available on the company's website after the completion of the conference: www.alligatorbioscience.com
Alligator is a research-based biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company is headquartered in Lund, Sweden, and had 35 employees per December 31, 2016. The Company is primarily active in the early stages of drug development, from the idea stage to clinical phase IIa studies, and Alligator’s product portfolio primarily consist of the product candidates ADC-1013, ATOR-1015 and ATOR-1016. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The company’s shares are listed on Nasdaq Stockholm under the ticker “ATORX”. For more information, visit www.alligatorbioscience.com.
For further information, please contact:
Rein Piir, VP Investor Relations
Telephone: +46 708 537292